Quick Answer
VERTEX PHARMACEUTICALS INC / MA reported Stockholders Equity of $18.67 billion for the year ending 2025.
- VERTEX PHARMACEUTICALS INC / MA showed an increase of +13.7% in Stockholders Equity from 2024 to 2025.
- This data is from VERTEX PHARMACEUTICALS INC / MA's annual report (Form 10-K), filed with the SEC on February 13, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2011: $307.55 million | Q3 2011: $579.76 million | Q1 2012: $930.50 million | Q2 2012: $1.04 billion | Q3 2012: $1.03 billion | Q1 2013: $746.12 million | Q2 2013: $1.32 billion | Q3 2013: $1.26 billion | Q1 2014: $1.23 billion | Q2 2014: $1.17 billion | Q3 2014: $1.16 billion | Q1 2015: $976.46 million | Q2 2015: $894.96 million | Q3 2015: $922.15 million | Q1 2016: $957.08 million | Q2 2016: $981.35 million | Q3 2016: $1.02 billion | Q1 2017: $1.50 billion | Q2 2017: $1.67 billion | Q3 2017: $1.79 billion | Q1 2018: $2.40 billion | Q2 2018: $2.69 billion | Q3 2018: $2.91 billion | Q2 2019: $5.07 billion | Q3 2019: $5.25 billion | Q1 2020: $6.46 billion | Q2 2020: $7.52 billion | Q3 2020: $8.13 billion | Q1 2021: $8.98 billion | Q2 2021: $9.20 billion | Q3 2021: $9.53 billion | Q1 2022: $10.91 billion | Q2 2022: $11.93 billion | Q3 2022: $13.03 billion | Q1 2023: $14.43 billion | Q2 2023: $15.47 billion | Q3 2023: $16.51 billion | Q1 2024: $18.55 billion | Q2 2024: $14.77 billion | Q3 2024: $15.63 billion | Q1 2025: $16.50 billion | Q2 2025: $17.18 billion | Q3 2025: $17.32 billion.
- Over the full 16 years of available data (2010 to 2025), VERTEX PHARMACEUTICALS INC / MA's Stockholders Equity has grown by 3,603.7%.
- Historical annual values: Fiscal year 2025: $18.67 billion | Fiscal year 2024: $16.41 billion | Fiscal year 2023: $17.58 billion | Fiscal year 2022: $13.91 billion | Fiscal year 2021: $10.10 billion | Fiscal year 2020: $8.69 billion | Fiscal year 2019: $6.09 billion | Fiscal year 2018: $4.44 billion | Fiscal year 2017: $2.03 billion | Fiscal year 2016: $1.16 billion | Fiscal year 2015: $939.97 million | Fiscal year 2014: $1.08 billion | Fiscal year 2013: $1.36 billion | Fiscal year 2012: $999.18 million | Fiscal year 2011: $786.84 million | Fiscal year 2010: $503.97 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: